Compared with the no-SGLT2-i group, prior coronary heart disease (57.1% vs. 42.7%, p = 0.008) or systolic heart failure (20% vs. 10.2%, p = 0.008) were more common in the SGLT2-i group. This evidence concerns the gene SLC5A2 and coronary artery disorder.